Serum Galectin-3 and Poor Outcomes Among Patients With Acute Ischemic Stroke [Brief Report]

Background and Purpose—Elevated galectin-3 has been associated with atherosclerosis and poor outcomes in patients with heart failure. However, it remains unclear whether galectin-3 has any effect on the poor outcomes of ischemic stroke. The aim of the present study was to examine the association between galectin-3 with poor outcomes among patients with acute ischemic stroke.Methods—Serum galectin-3 was measured in 3082 patients with acute ischemic stroke. The primary outcome was a combination of death or major disability (modified Rankin Scale score, ≥3) at 3 months after stroke.Results—Compared with the lowest quartile of galectin-3, multivariate adjusted odds ratios (95% confidence intervals) for the highest quartile of galectin-3 were 1.55 (1.15–2.09) for composite outcome, 2.10 (0.89–4.95) for death, and 1.43 (1.05–1.93) for major disability. The addition of galectin-3 to the conventional risk factors significantly improved prediction of the combined outcome of death or major disability in patients with ischemic stroke (net reclassification index, 18.9%; P

Source: Stroke - December 22, 2017 Category: Neurology Authors: Aili Wang, Chongke Zhong, Zhengbao Zhu, Tian Xu, Yanbo Peng, Tan Xu, Hao Peng, Chung-Shiuan Chen, Jinchao Wang, Zhong Ju, Qunwei Li, Deqin Geng, Yingxian Sun, Jianhui Zhang, Xiaodong Yuan, Jing Chen, Yonghong Zhang, Jiang He Tags: Biomarkers, Clinical Studies, Cerebrovascular Disease/Stroke Brief Reports Source Type: research